Grapevine: Aragen Life, Urban Company investors weigh stake sale

By Sreeja Biswas

  • 18 Sep 2024
Premium

Promoters and investors in Aragen Life Sciences, the Goldman Sachs-backed contract research organisation (CRO), plan to sell a 10% stake in a pre-IPO round, valuing the company at Rs 10,000-12,000 crore ($1.5 billion), a media report said.       Potential investors, including Quadria Capital and Denmark-based pharmaceutical firm Novo Nordisk, are in early talks for a minority stake, ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.